FDA approvals
2020 GLP-1 FDA approvals & regulatory actions
3 regulatory events affecting GLP-1 medications in 2020.
- New indication
Saxenda
FDA expanded Saxenda approval to pediatric patients aged 12 years and older with obesity — first GLP-1 for adolescent weight management.
Read on fda.gov → - New indication
Trulicity
FDA approved Trulicity for reducing risk of major adverse cardiovascular events in adults with T2D with or without established CV disease (REWIND trial).
Read on fda.gov → - New indication
Ozempic
FDA approved Ozempic for reducing risk of major adverse cardiovascular events in adults with T2D and established CV disease (SUSTAIN-6 trial).
Read on fda.gov →